^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    recombinant human bone morphogenetic protein 4 (HS214)

    i
    Other names: BMP4, hBMP4 , HS214
    Associations

    News

    Trials
    Company:
    Stemgen
    Drug class:
    Bone morphogenetic protein receptor type I modulator, Bone morphogenetic protein receptor type II modulator
    Associations

    News

    Trials
    2years
    A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients (clinicaltrials.gov)
    P1, N=15, Completed, Stemgen | Active, not recruiting --> Completed
    Trial completion
    |
    recombinant human bone morphogenetic protein 4 (HS214)
    over2years
    Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial. (PubMed, Mol Cancer)
    Local delivery of hrBMP4 in and around recurring glioblastoma is safe and well-tolerated. Three patients responded to the treatment. A complete response and long-term survival occurred in two of them. This warrants further clinical studies on this novel treatment targeting glioblastoma CSCs.
    P1 data • Journal
    |
    BMP4 (Bone Morphogenetic Protein 4)
    |
    recombinant human bone morphogenetic protein 4 (HS214)